Tolera Therapeutics Inc
Antigen-specific immunotherapy platform that selectively eliminates disease-causing immune cells
- Sector
- Biotech
- Headquarters
- KALAMAZOO, MI
- Founded
- 2006
- Latest Form D
- $250K, Sep 2014
- Total capital
- $13.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $13.9M
- 7 Form D · last Sep 2014
- 145 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 2 pending · first 2013
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 7th filing$250K
- Private capital raisedForm D · SEC · 6th filing$1.1M
- Private capital raisedForm D · SEC · 5th filing$5.4M
- Private capital raisedForm D · SEC · 4th filing$750K
- Private capital raisedForm D · SEC · 3rd filing$1.5M
- Private capital raisedForm D · SEC · 2nd filing$883K
- Private capital raisedForm D · SEC · 1st filing$4.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ashleigh PalmerExecutive OfficerNamed in SEC Form D filings
- Donald ParfetDirectorNamed in SEC Form D filings
- Douglas MortonDirectorNamed in SEC Form D filings
- James HerrmannExecutive OfficerNamed in SEC Form D filings
- John PuisisExecutive Officer, DirectorNamed in SEC Form D filings
- Mark OlesnavageDirectorNamed in SEC Form D filings
Show all 7 people
- Suzette DutchDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 5- PendingAntibody And Methods For Selective Inhibition Of T-cell ResponsesUSPTOApplication 14604069
- GrantedAntibody And Methods For Selective Inhibition Of T-cell ResponsesUSPTOUS 8,968,739
- GrantedAntibody And Methods For Selective Inhibition Of T-cell ResponsesUSPTOUS 8,722,049
Show all 5 patent records
- Antibody And Methods For Selective Inhibition Of T-cell ResponsesSep 10, 2015 · Application 14604069Pending
- Antibody And Methods For Selective Inhibition Of T-cell ResponsesMar 3, 2015 · US 8,968,739Granted
- Antibody And Methods For Selective Inhibition Of T-cell ResponsesMay 13, 2014 · US 8,722,049Granted
- Antibody And Methods For Selective Inhibition Of T-cell ResponsesOct 17, 2013 · Application 13844434Pending
- Antibody For Selective Inhibition Of T-cell ResponsesSep 3, 2013 · US 8,524,234Granted
Related companies, and why
- IMMUNEXT, INC.Similar federal contract value in Biotech · null in contracts
- NOVORON BIOSCIENCE INCSimilar federal contract value in Biotech · null in contracts
- ADAPTIN BIO, INC.Similar federal contract value in Biotech · null in contracts
- IllExcor Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- InMed Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- Sunstone Therapies, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .